| Identification | Back Directory | [Name]
4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OH, (DISULFIDE BOND) ACETATE | [CAS]
177943-89-4 | [Synonyms]
DOTA-(Tyr3)-Octreotete
7)-disulfide acetate (salt)
DOTA-(TYR3)-OCTREOTATE ACETATE
DOTA-(TYR3,THR8)-OCTREOTIDE ACETATE
DOTATATE, DOTA-(Tyr3,Thr8)-Octreotide
DOTA-[Tyr3]-Octreotate, DOTA-[Tyr3, Thr8]-Octreotide, DOTA-TATE
4,7,10-TricarboxyMethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH
4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OH, (DISULFIDE BOND) ACETATE
N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraaza-cyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-trypto-phyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic(2-7) disulfide
N-[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threonine cyclic (2→
N-[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threonine cyclic (2-7)-disulfide acetate (salt)
L-Threonine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-Dphenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2)-disulfide, acetate (salt) (9CI) | [Molecular Formula]
C65H92N14O19S2 | [MDL Number]
MFCD09039058 | [MOL File]
177943-89-4.mol | [Molecular Weight]
1437.65 |
| Chemical Properties | Back Directory | [Appearance]
Colourless to off-white lyophilised solid | [storage temp. ]
Store at -20°C, protect from light, stored under nitrogen | [solubility ]
PBS (pH 7.2): Slightly Soluble: 0.1-1 mg/ml | [form ]
Solid | [color ]
White to off-white | [InChIKey]
MGIRFLMPSDEBOD-MGZWADLVNA-N |
| Hazard Information | Back Directory | [Chemical Properties]
Colourless to off-white lyophilised solid | [Uses]
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT)[1][2][3][4]. DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs). | [in vivo]
177Lu-DOTATATE shows excellent antitumor effects in rats[1]. | [IC 50]
RDC Peptide | [References]
[1] Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. PMID:15653647
[2] Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. DOI:10.1097/MNM.0000000000001265
[3] Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. DOI:10.1007/s00259-003-1142-0
[4] Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. DOI:10.1007/s002590050034 |
|
|